Novel Bruton’s tyrosine kinase inhibitors currently in development

References

• KurosakiTTsukadaSBLNK: connecting Syk and Btk to calcium signalsImmunity2000121510661400
   PubMed Web of Science ®Google Scholar
• SchwartzbergPLFinkelsteinLDReadingerJATEC-family kinases: regulators of T-helper-cell differentiationNat Rev Immunol2005528429515803148
   PubMed Web of Science ®Google Scholar
• MahajanSVassilevASunNOzerZMaoCUckunFMTranscription factor STAT5A is a substrate of Bruton’s tyrosine kinase in B cellsJ Biol Chem2001276312163122811413148
   PubMed Web of Science ®Google Scholar
• GlassfordJSoeiroISkarellSMBCR targets cyclin D2 via Btk and the p85alpha subunit of PI3-K to induce cell cycle progression in primary mouse B cellsOncogene2003222248225912700661
   PubMed Web of Science ®Google Scholar
• BajpaiUDZhangKTeutschMSenRWortisHHBruton’s tyrosine kinase links the B cell receptor to nuclear factor kappaB activationJ Exp Med20001911735174410811866
   PubMed Web of Science ®Google Scholar
• PetroJBKhanWNPhospholipase C-gamma 2 couples Bruton’s tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytesJ Biol Chem20012761715171911042193
   PubMed Web of Science ®Google Scholar
• VassilevAOzerZNavaraCMahajanSUckunFMBruton’s tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complexJ Biol Chem1999274164616569880544
   PubMed Web of Science ®Google Scholar
• VerschurenMCKraakmanMEMensinkRGSchuurmanRKvan DongenJJHendriksRWThe Bruton’s tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stagesEur J Immunol199323310931148258324
   PubMed Web of Science ®Google Scholar
• MartinezNCamachoFIRuíz-BallesterosEVariability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvementClin Cancer Res2004106796680615501956
   PubMed Web of Science ®Google Scholar
• OrtolanoSHwangIYHanSBKehrlJHRoles for phosphoinositide 3-kinases, Bruton’s tyrosine kinase, and Jun kinases in B lymphocyte Chemotaxis and homingEur J Immunol2006361285129516619289
   PubMed Web of Science ®Google Scholar
• UckunFDibirdikISarkissianAQaziSIn vitro and in vivo chemosensitizing activity of LFM-A13, a dual-function inhibitor of Bruton’s tyrosine kinase and polo-like kinases, against human leukemic B-cell precursorsArzneimittelforschung20116125225921650085
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyWhat are the key statistics for chronic lymphocytic leukemia?2013 Available from: http://www.cancer.org/cancer/leukemia-chroniclymphocyticcll/detailedguide/leukemia-chronic-lymphocytic-key-statisticsAccessed February 5, 2013
   Google Scholar
• GaynonPSChildhood acute lymphoblastic leukaemia and relapseBr J Haematol200513157958716351633
   PubMed Web of Science ®Google Scholar
• GaynonPSTriggMUckunFMChildhood acute lymphoblastic leukemiaHollandJFreiEBastRCancer Medicine5th edHamilton (ON)BC Decker2000
   Google Scholar
• PuiCHEvansWETreatment of acute lymphoblastic leukemiaN Engl J Med200635416617816407512
   PubMed Web of Science ®Google Scholar
• Leukemia and Lymphoma SocietyLeukemia facts and statistics2012 Available from: http://www.lls.Org/#/diseaseinformation/getinformationsupport/factsstatistics/leukemiaAccessed February 5, 2013
   Google Scholar
• AbbottBLChronic lymphocytic leukemia: recent advances in diagnosis and treatmentOncologist200611213016401710
   PubMed Web of Science ®Google Scholar
• ByrdJCLinTSGreverMRTreatment of relapsed chronic lymphocytic leukemia: old and new therapiesSemin Oncol20063321021916616068
   PubMed Web of Science ®Google Scholar
• WierdaWGO’BrienSMInitial therapy for patients with chronic lymphocytic leukemiaSemin Oncol20063320220916616067
   PubMed Web of Science ®Google Scholar
• ChiorazziNRaiKRFerrariniMChronic lymphocytic leukemiaN Engl J Med200535280481515728813
   PubMed Web of Science ®Google Scholar
• PleyerLEgleAHartmannTNGreilRMolecular and cellular mechanisms of CLL: novel therapeutic approachesNat Rev Clin Oncol2009640541819488076
   PubMed Web of Science ®Google Scholar
• ZenzTMertensDKuppersRDohnerHStilgenbauerSFrom pathogenesis to treatment of chronic lymphocytic leukaemiaNat Rev Cancer201010375019956173
   PubMed Web of Science ®Google Scholar
• BurgerJAGhiaPRosenwaldACaligaris-CappioFThe microenvironment in mature B-cell malignancies: a target for new treatment strategiesBlood20091143367337519636060
   PubMed Web of Science ®Google Scholar
• SmitLAHallaertDYSpijkerRDifferential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacityBlood20071091660166817038534
   PubMed Web of Science ®Google Scholar
• HerishanuYPerez-GalanPLiuDThe lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemiaBlood201111756357420940416
   PubMed Web of Science ®Google Scholar
• StevensonFKKrysovSDaviesAJSteeleAJPackhamGB-cell receptor signaling in chronic lymphocytic leukemiaBlood20111184313432021816833
   PubMed Web of Science ®Google Scholar
• LinKGlennMAHarrisRJc-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implicationsCancer Res2006667801780916885384
   PubMed Web of Science ®Google Scholar
• TriggMEGaynonPUckunFMCancer Medicine4th edHollandJFBastRCJrMortonDLFryE3rdKufeDWWeichselbaumRLBaltimoreWilliams and Wilkins1996
   Google Scholar
• MorickeAZimmermannMReiterALong-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000Leukemia20102426528420010625
   PubMed Web of Science ®Google Scholar
• SalzerWLDevidasMCarrollWLLong-term results of the Pediatric Oncology Group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the Children’s Oncology GroupLeukemia20102435537020016527
   PubMed Web of Science ®Google Scholar
• GaynonPSHarrisREAltmanAJBone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children’s Oncology Group Study CCG-1941J Clin Oncol2006243150315616717292
   PubMed Web of Science ®Google Scholar
• EapenMRaetzEZhangMJOutcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in second remission: a collaborative study of the Children’s Oncology Group and the Center for International Blood and Marrow Transplant ResearchBlood20061074961496716493003
   PubMed Web of Science ®Google Scholar
• RoyACargillALoveSOutcome after first relapse in childhood acute lymphoblastic leukemia – lessons from the United Kingdom R2 trialBr J Hematol20051306775
   PubMed Web of Science ®Google Scholar
• UckunFMMorarSQaziSVinorelbine-based salvage chemotherapy for therapy-refractory aggressive leukemiasBr J Haematol200613550050817061978
   PubMed Web of Science ®Google Scholar
• MalempatiSGaynonPSSatherHLaMKStorkLCChildren’s Oncology GroupOutcome after relapse among children with standard-risk acute lymphoblastic leukemia: Children’s Oncology Group study CCG-1952J Clin Oncol2007255800580718089878
   PubMed Web of Science ®Google Scholar
• UckunFMJaszczWChandan-LanglieMWaddickKGGajl-PeczalskaKSongCWIntrinsic radiation resistance of primary clonogenic blasts from children with newly diagnosed B-cell precursor acute lymphoblastic leukemiaJ Clin Invest199391104410518450034
   PubMed Web of Science ®Google Scholar
• UckunF MSongCWLack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blastsBlood199381132313328443393
   PubMed Web of Science ®Google Scholar
• UckunFMChandan-LanglieMJaszczWObuzVWaddickKSongCWRadiation damage repair capacity of primary clonogenic blasts in acute lymphoblastic leukemiaCancer Res199353143114368443821
   PubMed Web of Science ®Google Scholar
• LarsonRAThe US trials in adult acute lymphoblastic leukemiaAnn Hematol200483Suppl 1S127S12815124704
   PubMedGoogle Scholar
• AnninoLVegnaMLCameraATreatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized studyBlood20029986387111806988
   PubMed Web of Science ®Google Scholar
• GoekbugetNArnoldRBuechnerTGanserAIntensification of induction and consolidation improves only subgroups of adult ALL: analysis of 1200 patients in GMALL study 05/93Blood200198802a
   Web of Science ®Google Scholar
• ThomasXBoironJMHuguetFOutcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trialJ Clin Oncol2004224075408615353542
   PubMed Web of Science ®Google Scholar
• NachmanJBSatherHNSenselMGAugmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapyNEnglJMed199833816631671
   PubMed Web of Science ®Google Scholar
• UckunFMTreating chronic leukemiasMinnesota Physician20021614
   Google Scholar
• EvrardSGaussemPHelleyDDarnigeLPrognostic factors in chronic lymphocytic leukaemia: contribution of recent biological markersAnn Biol Clin (Paris)200563589597 French16330377
   PubMed Web of Science ®Google Scholar
• KorteWCogliattiSChronic lymphocytic leukemia – the old and the newTher Umsch200461151156 German15018398
   PubMedGoogle Scholar
• PangalisGAVassilakopoulosTPDimopoulouMNSiakantarisMPKontopidouFNAngelopoulouMKB-chronic lymphocytic leukemia: practical aspectsHematol Oncol20022010314612203655
   PubMed Web of Science ®Google Scholar
• FariadeJrde OliveiraJSDelbone de FariaRMPrognosis related to staging systems for chronic lymphocytic leukemiaSao Paulo Med J2000118838810887382
   PubMedGoogle Scholar
• MorenoCVillamorNColomerDAllogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemiaJ Clin Oncol2005233433343815809449
   PubMed Web of Science ®Google Scholar
• KakuHHorikawaKObataYNF-kappaB is required for CD38-mediated induction of C(gamma) 1 germline transcripts inmurine B lymphocytesInt Immunol2002141055106412202402
   PubMed Web of Science ®Google Scholar
• UckunFMWaddickKGMahajanSBTK as a mediator of radiation-induced apoptosis in DT-40 lymphoma B cellsScience1996273109611008688094
   PubMed Web of Science ®Google Scholar
• TakatsuKRole of interleukin-5 in immune regulation and inflammationNippon Rinsho20046219411951 Japanese15500144
   PubMedGoogle Scholar
• Ruiz-BallesterosEMollejoMRodriguezASplenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysisBlood20061061831183815914563
   PubMed Web of Science ®Google Scholar
• TibesRTrentJKurzrockRTyrosine kinase inhibitors and the dawn of molecular cancer therapeuticsAnnu Rev Pharmacol Toxicol20054535738415822181
   PubMed Web of Science ®Google Scholar
• ChalandonYSchwallerJTargeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignanciesHaematologica20059094996815996933
   PubMed Web of Science ®Google Scholar
• KrauseDSEttenRATyrosine kinases as targets for cancer therapyN Engl J Med200535317218716014887
   PubMed Web of Science ®Google Scholar
• StillerCAInternational patterns of cancer incidence in adolescentsCancer Treat Rev20073363164517329031
   PubMed Web of Science ®Google Scholar
• GrossTGTermuhlenAMPediatric non-Hodgkin’s lymphomaCurr Oncol Rep2007945946517991353
   PubMedGoogle Scholar
• LenzGStaudtLMAggressive lymphomasN Engl J Med20103621417142920393178
   PubMed Web of Science ®Google Scholar
• MontiSSavageKJKutokJLMolecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory responseBlood20051051851186115550490
   PubMed Web of Science ®Google Scholar
• DavisRENgoVNLenzGChronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature2010463889220054396
   PubMed Web of Science ®Google Scholar
• DaviesAJRosenwaldAWrightGTransformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanismsBr J Haematol200713628629317278262
   PubMed Web of Science ®Google Scholar
• MontotoSFitzgibbonJTransformation of indolent B-cell lymphomasJ Clin Oncol2011291827183421483014
   PubMed Web of Science ®Google Scholar
• WenigerMAWiestnerAMolecular targeted approaches in mantle cell lymphomaSemin Hematol2011321422621782064
   PubMed Web of Science ®Google Scholar
• HermanSEGordonALHertleinEBruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood2011236287629621422473
   PubMed Web of Science ®Google Scholar
• MinterARSimpsonHWeissBMLandgrenOBone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunitiesSemin Hematol20111556521232659
   PubMed Web of Science ®Google Scholar
• RajeNRoodmanGDAdvances in the biology and treatment of bone disease in multiple myelomaClin Cancer Res201161278128621411443
   PubMed Web of Science ®Google Scholar
• AbeMHiuraKOzakiSKidoSMatsumotoTVicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1 alpha and MIP-lbeta productionJ Bone Miner Metab20091162319057841
   PubMed Web of Science ®Google Scholar
• ZannettinoACFarrugiaANKortesidisAElevated serum levels of stromal-derived factor-1 alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patientsCancer Res200551700170915753365
   PubMed Web of Science ®Google Scholar
• TakeuchiKAbeMHiasaMTGF-beta inhibition restores terminal osteoblast differentiation to suppress myeloma growthPLoS One20103e987020360846
   PubMed Web of Science ®Google Scholar
• ValletSMukherjeeSVaghelaNActivin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone diseaseProc Natl Acad Sci USA2010115124512920194748
   PubMed Web of Science ®Google Scholar
• MoreauxJVeyruneJLDe VosJKleinBAPRIL is overexpressed in cancer: link with tumor progressionBMC Cancer200998319291294
   PubMed Web of Science ®Google Scholar
• TaiYTLiXFBreitkreutzIRole of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironmentCancer Res2006136675668216818641
   PubMed Web of Science ®Google Scholar
• KlineMDonovanKWellikLCytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progressionLeuk Res2007559159816879867
   PubMed Web of Science ®Google Scholar
• LeeSHKimTJeongDKimNChoiYThe tec family tyrosine kinase Btk regulates RANKL-induced osteoclast maturationJ Biol Chem200817115261153418281276
   PubMed Web of Science ®Google Scholar
• TaiYTChangBYKongSYBruton’s tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaBlood20121201877188722689860
   PubMed Web of Science ®Google Scholar
• EifertCAn RNAi Screen Targeting the Protein Tyrosine Kinases Identifies Bruton’s Tyrosine Kinase (BTK) as a Breast Cancer Cell Survival Factor [dissertation]AlbanyState University of New York2009
   Google Scholar
• ConklinDSEifertCKourtidisABruton’s tyrosine kinase as anti-cancer drug targetUS patent application 201201653956282012
   Google Scholar
• LavitranoMGrassilliEHelinKIsoform of bruton’s tyrosine kinase (BTK) proteinUS patent 8,232,0857312012
   Google Scholar
• UckunFMZhengYGhoshSBTK inhibitors and methods for their identification and useUS patent 6,160,01012122000
   Google Scholar
• UckunFMZhengYGhoshSBTK inhibitors and methods for their identification and useUS patent 6,221,9004242001
   Google Scholar
• UckunFMZhengYGhoshSBTK inhibitors and methods for their identification and useUS patent 6,294,5759252001
   Google Scholar
• UckunFMZhengYGhoshSBTK inhibitors and methods for their identification and useUS patent 6,303,65210162001
   Google Scholar
• UckunFMZhengYGhoshSBTK inhibitors and methods for their identification and useUS patent 6,365,626422002
   Google Scholar
• UckunFMMalaviyaRBTK inhibitors and methods for their identification and useUS patent 6,753,3486222004
   Google Scholar
• UckunFMZhengYGhoshSBTK Inhibitors and methods for their identification and use European patent 1 071 658 B16162004
   Google Scholar
• ZhuZIntrabodiesUS patent application 201001433716102010
   Google Scholar
• HonigbergLInhibitors of Bruton’s tyrosine kinaseUS patent application 201000416772182010
   Google Scholar
• HonigbergLVernerEPanZInhibitors of Bruton’s tyrosine kinaseUS patent application 201000225611282010
   Google Scholar
• HonigbergLVernerEPanZInhibitors of Bruton’s tyrosine kinaseUS patent application 20100004270172010
   Google Scholar
• HonigbergLVernerEPanZInhibitors of Bruton’s tyrosine kinaseUS patent application 200801395826122008
   Google Scholar
• TrippMBabishJBlandJSubstituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewithUS patent application 201001374496102010
   Google Scholar
• Kennedy-SmithJKondruRKLoeBEInhibitors of Bruton’s tyrosine kinaseUS patent application 201000996594222010
   Google Scholar
• JankowskiODPalmerJTHonigbergLInhibitors of tyrosine kinases and uses thereofUS patent application 201000358412112010
   Google Scholar
• JohnsRASuQChampionHCHIMF and BTK in pulmonary, cardiac, and inflammation disordersUS patent application 20100028355242010
   Google Scholar
• DewdneyNJLouYSjogrenESothMSweeneyZKInhibitors of Bruton’s tyrosine kinaseUS patent application 20100004231172010
   Google Scholar
• DewdneyNJKondruRKLoeBEInhibitors of Bruton’s tyrosine kinaseUS patent application 2009031844812242009
   Google Scholar
• DewdneyNJKennedy-SmithJKondruRKInhibitors of Bruton’s tyrosine kinaseUS patent application 2009030604112102009
   Google Scholar
• DewdneyNJLouYSjogrenESothMInhibitors of Bruton’s tyrosine kinaseUS patent application 201000163011212010
   Google Scholar
• PanZScheerensHLiSJDiscovery of selective irreversible inhibitors of Bruton’s tyrosine kinaseChem Med Chem20072586117154430
   PubMed Web of Science ®Google Scholar
• HonigbergLASmithAMSirisawadMThe Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProc Natl Acad Sci USA2010107130751308020615965
   PubMed Web of Science ®Google Scholar
• SinghJPetterRCKlugeAFTargeted covalent drugs of the kinase familyCurr Opin Chem Biol2010141620022288
   PubMed Web of Science ®Google Scholar
• EvansETesterRAslanianSA novel platform-based approach to silence oncoproteins using small molecule therapeutics – application to Bruton’s tyrosine kinasePaper presented at the 100th AACR Annual MeetingApril 18–22, 2009Denver, CO, USA
   Google Scholar
• MarcotteDJLiuYTArduiniRMStructures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinasesProtein Sci20101942943920052711
   PubMed Web of Science ®Google Scholar
• HantschelORixUSchmidtUThe Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinibProc Natl Acad Sci USA2007104132831328817684099
   PubMed Web of Science ®Google Scholar
• MaoCZhouMUckunFMCrystal structure of Bruton’s tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemiaJ Biol Chem2001276414354144311527964
   PubMed Web of Science ®Google Scholar
• HermanSEGordonALHertleinEBruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood2011236287629621422473
   PubMed Web of Science ®Google Scholar
• PonaderSChenSSBuggyJJBruton’s tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoBlood20121191182118922180443
   PubMed Web of Science ®Google Scholar
• de RooijMFKuilAGeestCRThe clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemiaBlood20121192590259422279054
   PubMed Web of Science ®Google Scholar
• ChangBYHuangMMFrancescoMThe Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cellsArthritis Res Ther20114R11521752263
   PubMed Web of Science ®Google Scholar
• HollerCPinonJDDenkUPKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemiaBlood20091132791279419168795
   PubMed Web of Science ®Google Scholar
• GorgunGRamsayAGHolderriedTAE(μ)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunctionProc Natl Acad Sei USA200910662506255
   PubMed Web of Science ®Google Scholar
• JohnsonAJLucasDMMuthusamyNCharacterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemiaBlood20061081334133816670263
   PubMed Web of Science ®Google Scholar
• BurgerJAO’BrienSFowlerNThe Bruton’s tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): an update on ongoing phase 1 studiesBlood201011632a
   Web of Science ®Google Scholar
• AdvaniRSharmanJPSmithSMEffect of Btk inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: evidence of antitumor activity from a phase I study [abstract]J Clin Oncol20102815s
   PubMed Web of Science ®Google Scholar
• AdvaniRSharmanJSmithSTThe Btk inhibitor PCI-32765 is highly active and well tolerated in patients with relapsed/refractory B cell malignancies: final results from a phase I studyAnn Oncol201122Suppl 4ivl35ivl37
   Google Scholar
• AdvaniRHBuggyJJSharmanJPBruton tyrosine kinase inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignanciesJ Clin Oncol201331889423045577
   PubMed Web of Science ®Google Scholar
• FowlerNSharmanJPSmithSMThe Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study. ASH Annual Meeting AbstractsBlood2010116964A
   Web of Science ®Google Scholar
• FowlerNHAdvaniRHSharmanJPThe Bruton’s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphomaPaper presented at the 2012 ASH Annual MeetingDecember 8–11, 2012Atlanta, GA, USAAbstract 156
   Google Scholar
• StaudtLMDunleavyKBuggyJJThe Bruton’s tyrosine kinase (Btk) inhibitor PCI-32765 modulates chronic active BCR signaling and induces tumor regression in relapsed/refractory ABC DLBCLBlood (ASH Annual Meeting Abstract)2011118abstract 2716
   Web of Science ®Google Scholar
• HarrisonCTrial watch: BTK inhibitor shows positive results in B cell malignanciesNat Rev Drug Discov2012119622262035
   PubMed Web of Science ®Google Scholar
• WangMRuleSAMartinPInterim results of an international, multicenter, phase 2 study of Bruton’s tyrosine kinase (BTK) inhibitor, Ibrutinib (PCI-32765), in relapsed or refractory mantle cell lymphoma (MCL): durable efficacy and tolerability with longer follow-up2012 ASH Annual MeetingDecember 8–11, 2012Atlanta, GA, USAAbstract 904
   Google Scholar
• PonaderPBalasubramanianSPhamLVActivity of Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 in mantle cell lymphoma (MCL) identified BTK as a novel therapeutic target53rd ASH Annual MeetingDecember 10–13, 2011San Diego, CA, USAAbstract 3688
   Google Scholar
• WilsonWHGerecitanoJFGoyAThe Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study2012 ASH Annual MeetingDecember 8–11, 2012Atlanta, GA, USAAbstract 686
   Google Scholar
• O’BrienSBurgerJABlumKAThe Bruton’s Tyrosine Kinase Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study53rd ASH Annual MeetingDecember 10–13, 2011San Diego, CA, USAAbstract 983
   Google Scholar
• O’BrienSBurgerJACoutreSEThe Btk Inhibitor PCI-32765 is highly active and tolerable in patients with poor-risk CLL: interim results from a phase Ib/II studyAnn Oncol201122Suppl 4ivl23ivl24
   Google Scholar
• O’BrienSBurgerJABlumKAThe Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 induces durable responses in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): follow-up of a phase Ib/II studyBlood2011118449
   Web of Science ®Google Scholar
• O’BrienSFurmanRFCoutreSEThe Bruton’s tyrosine kinase inhibitor ibrutinib (PCI-32765) is highly active and tolerable in relapsed or refractory and treatment naive chronic lymphocytic leukemia patients, updated results of a phase Ib/II study17th Congress of European Hematology AssociationJune 14–17, 2012Amsterdam, The Netherlands2012Abstract 1970
   Google Scholar
• ByrdJCFurmanRRCoutreSEThe Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): interim results of a phase Ib/II studyJ Clin Oncol2012Suppl 306507
   Google Scholar
• ByrdJCFurmanRRCoutreSFlinnIWBurgerJABlumKAThe Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) CLL or SLL patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II Study2012 ASH Annual MeetingDecember 8–11, 2012Atlanta, GA, USAAbstract 189
   Google Scholar
• BurgerJAKeatingMJWierdaWGThe Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients2012 ASH Annual MeetingDecember 8–11, 2012Atlanta, GA, USAAbstract 187
   Google Scholar
• BrownJRBarrientosJFlinnIWCombination of the Bruton’s tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia: interim results of a phase Ib/II study17th Congress of European Hematology AssociationAmsterdam, The NetherlandsJune 14–17, 2012Abstract 1590
   Google Scholar
• O’BrienSMBarrientosJCFlinnIWCombination of the Bruton’s tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): interim results of a phase Ib/II studyJ Clin Oncol2012Suppl 306515
   Google Scholar
• JaglowskiSMJonesJAFlynnJMA phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseasesJ Clin Oncol2012Suppl 306508
   Google Scholar
• AdvaniRSharmanJPSmithSMEffect of BTK inhibitor PCI-32765 monotherapy on responses in patients with relapsed aggressive NHL: evidence of anti-tumor activity from a phase I studyJ Clin Oncol2010Suppl 288012
   Web of Science ®Google Scholar
• SinghJRussellPDeqiangNProtein kinase conjugates and inhibitorsUS patent application 201101170735192011
   Google Scholar
• EvansETesterRAslanianSA novel platform-based approach to silence oncoproteins using small molecule therapeutics–application to Bruton’s tyrosine kinaseProceedings of the 103rd Annual Meeting of the American Association for Cancer ResearchApril 18–22, 2009Denver, CO, USAAbstract 3739
   Google Scholar
• EvansESheetsMBernarHProlonged inhibition of BCR signaling and suppression of B cell lymphoma through irreversible inhibition of Bruton’s tyrosine kinase [abstract]Blood2008112904
   Web of Science ®Google Scholar
• EvansEPonaderSKarpRCovalent inhibition of Btk with clinical development compound AVL-292 disrupts signaling that maintains the microenvironment necessary for chronic lymphocytic leukemia growth [abstract]Clin Lymphoma Myeloma Leuk201111Suppl2S173S174
   Google Scholar
• EdaHSantoLCirsteaDDTargeting Bruton’s tyrosine kinase as a novel approach to inhibit osteoclast function in multiple myeloma [abstract]Blood20111181243
   Web of Science ®Google Scholar
• EvansETesterRSharonATranslational medicine of a selective inhibitor of Btk in rheumatic diseases: pharmacology and early clinical development [abstract]Arthritis Rheum201163Suppl 101757
   Google Scholar
• EvansETesteRAslanianSClinical development of AVL-292; a potent, selective covalent Btk inhibitor for the treatment of B cell malignancies [abstract]Blood20111181487
   Web of Science ®Google Scholar
• WestlinWFStiedeKLounsburyHTranslational medicine enables rapid early clinical development of AVL-292, a highly selective, orally available inhibitor of Bruton’s tyrosine kinase, in a phase lb clinical trialCancer Res201272Suppl 81745
   Web of Science ®Google Scholar
• HantschelORixUSuperti-FurgaGTarget spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinibLeuk Lymphoma20084961561918398720
   PubMed Web of Science ®Google Scholar
• HallaertDYJaspersAvan NoeselCJvan OersMHKaterAPEideringEAbl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant nichesBlood20081125141514918796631
   PubMed Web of Science ®Google Scholar
• ElderingEGeestCRde RooijMFMMapping the targets of dasatinib in chronic lymphocytic leukemia reveals distinct roles for Abl and Btk in drug resistance and adhesion, and explains clinical effects on lymph node reductionProceedings: 2012 ASH Annual MeetingDecember 8–11, 2012Atlanta, GA, USAAbstract 3900
   Google Scholar
• AmreinPCAttarECTakvorianTPhase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemiaClin Cancer Res2011172977298621402714
   PubMed Web of Science ®Google Scholar
• MahajanSGhoshSSudbeckEARational design and synthesis of a novel anti-leukemic agent targeting Bruton’s tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide]J Biol Chem19992749587959910092645
   PubMed Web of Science ®Google Scholar
• GhoshSJennissenJDZhengYUckunFMThree leflunomide metabolite analogsActa Crystallogr C2000561254125711025316
   PubMedGoogle Scholar
• KimYJSekiyaFPoulinBBaeYSRheeSGMechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2Mol Cell Biol2004249986999915509800
   PubMed Web of Science ®Google Scholar
• HeinonenJESmithCINoreBESilencing of Bruton’s tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA)FEBS Lett200252727427812220673
   PubMed Web of Science ®Google Scholar
• UckunFMOzerZQaziSTuel-AhlgrenLMaoCPolo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stressBr J Haematol201014871472519912216
   PubMed Web of Science ®Google Scholar
• UckunFMDibirdikIQaziSAnti-breast cancer activity of LFM-A13, a potent inhibitor of polo-like kinase (PLK)Bioorg Med Chem20071580081417098432
   PubMed Web of Science ®Google Scholar
• UckunFMChemosensitizing anti-cancer activity of LFM-A13, a leflunomide metabolite analog targeting polo-like kinasesCell Cycle200763021302618073537
   PubMed Web of Science ®Google Scholar
• UckunFMRationally designed anti-mitotic agents with pro-apoptotic activityCurr Pharm Des2001716273911562303
   PubMed Web of Science ®Google Scholar
• UckunFMZhengYCetkovic-CvrljeMIn vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13), a novel antileukemic agent targeting Bruton’s tyrosine kinaseClin Cancer Res200281224123312006542
   PubMed Web of Science ®Google Scholar
• Cetkovic-CvrljeMUckunFMDual targeting of Bruton’s tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation modelBr J Hematol2004126821827
   PubMed Web of Science ®Google Scholar
• KozakiRYoshizawaTYasuhiroTDevelopment of a Bruton’s tyrosine kinase (Btk) inhibitor–ONO-WG-307, a potential treatment for B-cell malignanciesCancer Res201272Suppl B857
   Web of Science ®Google Scholar
• YasuhiroTYoshizawaTDaubHWeberCNaritaMKawabataKONO-WG-307, a novel, potent and selective inhibitor of Bruton’s tyrosine kinase (Btk), results in sustained inhibition of the ERK, AKT and PKD signaling pathwaysCancer Res201272Suppl B2021
   Web of Science ®Google Scholar
• LiuLDi PaoloJBarbosaJRongHReifKWongHAntiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacyJ Pharmacol Exp Ther201133815416321521773
   PubMed Web of Science ®Google Scholar
• LiuLHalladayJSShinYSignificant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase inhibitorDrug Metab Dispos2011391840184921742900
   PubMed Web of Science ®Google Scholar